iifl-logo

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

Sequent Scientific acquires 100% stake in Brazil-based firm 'Nourrie' for $5 million

3 Mar 2022 , 01:50 PM

SeQuent Scientific Limited (SeQuent), having businesses in animal health sector through its principal operating company “Alivira Animal Health Ltd. (Alivira)”, has completed the acquisition of 100% stake in Nourrie Saúde e Nutrição Animal Ltda (Nourrie) in Brazil. This acquisition has been made through Alivira Saúde Animal Ltda Brazil, a wholly owned subsidiary of Alivira, for a total cash consideration of BRL 27 Million (~USD 5 Million), said Company.

SeQuent had originally announced signing of the binding agreement to acquire Nourrie on 16th December 2021. The conclusion of Nourrie’s acquisition marks an important milestone in Sequent 2.0 strategy of establishing presence in Brazil’s pet market, the fastest growing segment. Brazil has the 4 th largest pet market in the world with an estimated market size of BRL 1.8 Billion, growing annually at ~16%.

The addition of Nourrie’s business has nearly doubled the product portfolio available to Alivira for commercialization in Brazil, with additions in both the nutraceutical and therapeutic product categories. Nourrie also brings a strong pipeline of 20 products under development, 12 of which are planned for launch in the next fiscal.

The acquisition also provides Alivira complete control over the value-chain of Transuin, a Ractopamine based swine product currently manufactured at Nourrie, which is at present the 3rd largest product in Alivira Brazil’s portfolio. With access to Alivira’s own API manufactured in the USFDA approved plant at Vizag, and extension of product range with upcoming registration approvals, Alivira intends to fast-track growth for Transuin franchise in both Brazil and other Latam markets. The expansion of swine and poultry segment will be further catalysed with nearly 5 new product launches expected in the near term.

Consequent to the oversight of Alivira management, Nourrie’s pet business outlook has been promising, with monthly revenues having grown by 50%+ in February 2022, compared to those at the time of acquisition announcement in December 2021.

Alivira already has an established track-record of performance in Brazil, with the local operations growing 5-fold at a CAGR of 57% over last 5 years. Brazil has emerged as the third largest market for Alivira, next only to Spain and Turkey.

At around 1:53 PM, Sequent Scientific was trading at Rs130.05 apiece up by Rs0.05 or 0.04% on the BSE.

Related Tags

  • acquisition
  • Brazil acquisition
  • business update
  • market
  • news
  • Nutrição Animal
  • Sequent Scientific Ltd
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.